← Leaderboards
Aaron D Fox
Albert Einstein College Of Medicine
$6,420,892
Attributed
$6,878,799
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,878,799 · 5
By mechanism
R01$3,747,016 · 1
R61$915,814 · 1
K23$912,980 · 1
R34$748,577 · 1
K24$554,412 · 1
Top collaborators
- Teresa Lopez-Castro1 shared
Most similar at Albert Einstein College Of Medicine
Same institution · by research overlap
- Stephen P Wall$6,631,760
- Anjali Sharma$19,812,193
- Nina Cooperman$7,023,812
Others in their field
Top investigators on “Buprenorphine”
- Sharon L. Walsh · University Of Kentucky$87,310,858
- Edward V Nunes · Columbia University Health Sciences$83,345,625
- T John Winhusen · University Of Cincinnati$34,249,969
- Walter Nmn Ling · University Of California Los Angeles$33,859,118
- Marco Pravetoni · Hennepin Healthcare Research Institute$33,709,846
- George E Woody · University Of Pennsylvania$33,075,022
Research focus
BuprenorphineParticipantRisk BehaviorsEffectivenessMedicalOverdoseHiv RiskPrimary OutcomeCaringRandomizedTrainingBaseUnited StatesCessation Of LifeTreatment OutcomeAddictionHigh RiskHiv InfectionsGrantStructurePhysiciansFrequenciesProviderPublic Health
Grant awards (23)
Mentorship in research on opioid use disorder treatment and HIV prevention$184,804
K24 · FY2025 · DA · contact PI
Mentorship in research on opioid use disorder, HIV and marginalized populations$184,804
K24 · FY2024 · DA · contact PI
Onsite PTSD Treatment to Improve MOUD Outcomes (OPTIMO): a hybrid Type 1 effectiveness-implementation trial of harm reduction PTSD care at syringe service programs$915,814
R61 · FY2023 · DA
Mentorship in research on opioid use disorder, HIV and marginalized populations$184,804
K24 · FY2023 · DA · contact PI
Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk$665,462
R01 · FY2022 · DA · contact PI
Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk$723,410
R01 · FY2021 · DA · contact PI
Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk$93,845
R01 · FY2021 · DA · contact PI
Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk$719,596
R01 · FY2020 · DA · contact PI
Impact of PTSD and trauma reexposure on buprenorphine maintenance treatment in syringe exchange programs$103,720
R01 · FY2020 · DA · contact PI
Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk$454,931
R01 · FY2018 · DA · contact PI
Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk$264,665
R01 · FY2018 · DA · contact PI
Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk$721,387
R01 · FY2017 · DA · contact PI
Buprenorphine group medical visits for drug users at risk for HIV$236,981
R34 · FY2017 · DA · contact PI
Buprenorphine group medical visits for drug users at risk for HIV$55,269
R34 · FY2017 · DA · contact PI
Buprenorphine group medical visits for drug users at risk for HIV$289,327
R34 · FY2016 · DA · contact PI
Buprenorphine Facilitated Access and Supportive Treatment in Former Inmates$182,596
K23 · FY2016 · DA · contact PI
Buprenorphine Facilitated Access and Supportive Treatment in Former Inmates$152,165
K23 · FY2015 · DA · contact PI
Buprenorphine group medical visits for drug users at risk for HIV$97,417
R34 · FY2015 · DA · contact PI
Buprenorphine group medical visits for drug users at risk for HIV$69,583
R34 · FY2015 · DA · contact PI
Buprenorphine Facilitated Access and Supportive Treatment in Former Inmates$30,431
K23 · FY2015 · DA · contact PI
Buprenorphine Facilitated Access and Supportive Treatment in Former Inmates$182,596
K23 · FY2014 · DA · contact PI
Buprenorphine Facilitated Access and Supportive Treatment in Former Inmates$182,596
K23 · FY2013 · DA · contact PI
Buprenorphine Facilitated Access and Supportive Treatment in Former Inmates$182,596
K23 · FY2012 · DA · contact PI